Literature DB >> 18597042

Atomic model of human cystic fibrosis transmembrane conductance regulator: membrane-spanning domains and coupling interfaces.

J-P Mornon1, P Lehn, I Callebaut.   

Abstract

We describe herein an atomic model of the outward-facing three-dimensional structure of the membrane-spanning domains (MSDs) and nucleotide-binding domains (NBDs) of human cystic fibrosis transmembrane conductance regulator (CFTR), based on the experimental structure of the bacterial transporter Sav1866. This model, which is in agreement with previous experimental data, highlights the role of some residues located in the transmembrane passages and directly involved in substrate translocation and of some residues within the intracellular loops (ICL1-ICL4) making MSD/NBD contacts. In particular, our model reveals that D173 ICL1 and N965 ICL3 likely interact with the bound nucleotide and that an intricate H-bond network (involving especially the ICL4 R1070 and the main chain of NBD1 F508) may stabilize the interface between MSD2 and the NBD1F508 region. These observations allow new insights into the ATP-binding sites asymmetry and into the molecular consequences of the F508 deletion, which is the most common cystic fibrosis mutation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18597042     DOI: 10.1007/s00018-008-8249-1

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  82 in total

1.  Differential contribution of TM6 and TM12 to the pore of CFTR identified by three sulfonylurea-based blockers.

Authors:  Guiying Cui; Binlin Song; Hussein W Turki; Nael A McCarty
Journal:  Pflugers Arch       Date:  2011-12-13       Impact factor: 3.657

2.  Thermal instability of ΔF508 cystic fibrosis transmembrane conductance regulator (CFTR) channel function: protection by single suppressor mutations and inhibiting channel activity.

Authors:  Xuehong Liu; Nicolette O'Donnell; Allison Landstrom; William R Skach; David C Dawson
Journal:  Biochemistry       Date:  2012-06-15       Impact factor: 3.162

3.  Alternating access to the transmembrane domain of the ATP-binding cassette protein cystic fibrosis transmembrane conductance regulator (ABCC7).

Authors:  Wuyang Wang; Paul Linsdell
Journal:  J Biol Chem       Date:  2012-02-01       Impact factor: 5.157

4.  Small molecule correctors of F508del-CFTR discovered by structure-based virtual screening.

Authors:  Ori Kalid; Martin Mense; Sharon Fischman; Alina Shitrit; Hermann Bihler; Efrat Ben-Zeev; Nili Schutz; Nicoletta Pedemonte; Philip J Thomas; Robert J Bridges; Diana R Wetmore; Yael Marantz; Hanoch Senderowitz
Journal:  J Comput Aided Mol Des       Date:  2010-10-26       Impact factor: 3.686

5.  Physiological and pharmacological characterization of the N1303K mutant CFTR.

Authors:  Samantha DeStefano; Maarten Gees; Tzyh-Chang Hwang
Journal:  J Cyst Fibros       Date:  2018-06-07       Impact factor: 5.482

6.  A posttranslational modification code for CFTR maturation is altered in cystic fibrosis.

Authors:  Sandra Pankow; Casimir Bamberger; John R Yates
Journal:  Sci Signal       Date:  2019-01-01       Impact factor: 8.192

7.  Cooperative assembly and misfolding of CFTR domains in vivo.

Authors:  Kai Du; Gergely L Lukacs
Journal:  Mol Biol Cell       Date:  2009-01-28       Impact factor: 4.138

8.  Impact of the F508del mutation on ovine CFTR, a Cl- channel with enhanced conductance and ATP-dependent gating.

Authors:  Zhiwei Cai; Timea Palmai-Pallag; Pissared Khuituan; Michael J Mutolo; Clément Boinot; Beihui Liu; Toby S Scott-Ward; Isabelle Callebaut; Ann Harris; David N Sheppard
Journal:  J Physiol       Date:  2015-04-09       Impact factor: 5.182

Review 9.  The gating of the CFTR channel.

Authors:  Oscar Moran
Journal:  Cell Mol Life Sci       Date:  2016-10-01       Impact factor: 9.261

Review 10.  Dynamics intrinsic to cystic fibrosis transmembrane conductance regulator function and stability.

Authors:  P Andrew Chong; Pradeep Kota; Nikolay V Dokholyan; Julie D Forman-Kay
Journal:  Cold Spring Harb Perspect Med       Date:  2013-03-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.